Trevi Therapeutics CFO Lisa Delfini to depart Aug 22; CEO to serve as interim principal financial officer

Trevi Therapeutics, Inc.

CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.
CEO Jennifer L. Good will serve as interim principal financial officer until a permanent CFO is appointed.
Delfini will receive separation benefits under the Executive Separation Benefits and Retention Plan, subject to a severance and release agreement.
No details provided on search for permanent CFO or timeline.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.